FGFR3 and bladder transitional cell carcinoma: In addition to traditional chemotherapy27, a variety of new therapeutic agents including immune checkpoint therapy, FGFR3 inhibitor, and antibody-drug conjugates have been approved by the FDA for the treatment of metastatic BLCA as recently reviewed28.